Dr María Díez‐Campelo (Spain): P3 IMerge (MDS).....

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
kmall
Posts: 753
Joined: Thu Mar 21, 2019 3:57 pm

Dr María Díez‐Campelo (Spain): P3 IMerge (MDS).....

Post by kmall » Fri Oct 28, 2022 3:52 am

Apparently, Dr María Díez‐Campelo (Spain): P3 IMerge (MDS) will be a Keynote Speaker at an offshoot of ASH on the Friday Satellite Symposia in Tampa, FL...... sponsored by Geron. Courtesy of Kaz on the YMB.....

AN EXPERT DISCUSSION ON MYELODYSPLASTIC SYNDROMES: CURRENT AND FUTURE PERSONALIZED MANAGEMENT APPROACHES

This program is supported by educational grants from Bristol Myers Squibb; Geron Corporation; Karyopharm Therapeutics Inc.; and Novartis Pharmaceuticals Corporation

Dec 9, 2022: 11:00 a.m. - 2:00 p.m. Central time
Sheraton New Orleans
Napoleon B 1-3 + Corridor A/B

New innovations have changed clinical practice in the management of myelodysplastic syndromes (MDS) and this interactive symposium will focus on evolving therapeutic standards and emerging therapeutic options with expert faculty providing practical insights for disease and supportive care management of MDS across the spectrum of low- to high-risk disease and following HMA failure. Using different case presentations, the experts will discuss key clinical questions, available supporting evidence, and challenges that affect therapeutic decisions as well as their individual treatment recommendations for each case. Throughout the symposium, the audience will be able to vote on case scenarios and directly text questions regarding their specific challenges to the panel for their consideration. Discussion topics will include:
Risk stratification in MDS
Managing anemia in very low–risk, low-risk, or intermediate-risk MDS
Novel therapeutic approaches for the treatment of lower-risk MDS
Latest guidance on the treatment of higher-risk MDS and managing relapsed/refractory MDS
CHAIR:

Rami S. Komrokji
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL

SPEAKERS:

María Diez-Campelo, MD, PhD
University Hospital of Salamanca
Salamanca, Spain

Amer M. Zeidan, MD
Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center
New Haven, CT


Friday Satellite Symposia*

FSS* are industry-supported, CME-certified symposia. These sessions are NOT part of the official ASH annual meeting program and are planned solely by the SPONSORING company. The 2022 FSS will take place on Friday, December 9, 2022.
Less
--------------------------------------------------------------------------------
Earlier this year, Dr. María Diez-Campelo and two abstracts on Imetelstat featuring her contributions were highlighted on Imetechat in "Somebody Call Me A Doctor........... Champions of Imetelstat"......

viewtopic.php?f=1&t=1295


Dr María Díez‐Campelo (Spain): P3 IMerge (MDS)
https://mds-europe.org/right/partners/iecscyl

Specified Indications: MDS

P3 Site Location: Hosp. Clinico Univ. de Salamanca – Salamanca, Spain

Geron Abstracts/Affiliations:
1 – (2021) On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)
Valeria Santini, Pierre Fenaux, Koen Van Eygen, Azra Raza, Ulrich Germing, Patricia Font, Maria Diez-Campelo, Sylvain Thepot, Edo Vellenga, Mrinal M. Patnaik, Jun Ho Jang, Laurie Sherman, Tymara Berry, Faye Feller, Souria Dougherty, Libo Sun, Ying Wan, Aleksandra Rizo, Fei Huang, Uwe Platzbecker

https://ashpublications.org/blood/artic ... lates-with

2 – (2018) Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naïve
David P. Steensma, Uwe Platzbecker, Koen Van Eygen, Azra Raza, MD, Valeria Santini, Ulrich Germing, MD, Patricia Font, MD, Irina Samarina, MD, Maria Díez-Campelo, Sylvain Thepot, MD, Edo Vellenga, Mrinal M. Patnaik, MDMBBS, Jun Ho Jang, MD PhD, Jacqueline Bussolari, PhD, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Pierre Fenaux
https://ashpublications.org/blood/artic ... ransfusion



**With P3 IMerge Clinicians/Physicians speaking publically on the progress/future of Imetelstat and today's PR from Geron, it sure does feel like the volume is being turned up to 11........... isn't that right Nigel?

https://www.google.com/search?q=this+on ... OO5S4vxi0o


Thanks for the info Kaz! -Kmall

biopearl123
Posts: 1665
Joined: Fri Jul 20, 2018 5:13 pm

Re: Dr María Díez‐Campelo (Spain): P3 IMerge (MDS).....

Post by biopearl123 » Fri Oct 28, 2022 5:08 am


kmall
Posts: 753
Joined: Thu Mar 21, 2019 3:57 pm

Re: Dr María Díez‐Campelo (Spain): P3 IMerge (MDS).....

Post by kmall » Fri Oct 28, 2022 12:41 pm

Bp - Unfortunately I am quite familiar with the Smillow Cancer Center at Yale University Hospital in New Haven, CT - affiliated with Dr. Amer M. Zeidan. My father in-law was diagnosed with Guillain-Barre Syndrome (GBS) back in 2011 and was in Yale Neurology ICU for several weeks before being transferred to Smillow for additional treatment with other underlying conditions. It is a world class facility, and had he not gone directly to Yale for diagnosis, his circumstances most likely would have been much different. He's still alive today, albeit with about 70% capacity of pre-GBS. Prior to his diagnosis, I had never heard of GBS. A quite frightful virus that can affect anyone, at any age, at anytime, although some are more prone than others. Yale Hospital happened to have four other GBS cases there at the time of his diagnosis - a 9yr old girl and patients aged up to 60+ years old - he was 64yrs old at the time. When we walked into Neurology at Yale, Physicians there told us they were 95% certain of what he had, but had to run a few tests for confirmation. There may be some correlation between GBS and the flu shot, from some of the brief research I was able to do 11+ years ago. I do know that when I received the JNJ one time COVID vaccination, GBS was on the list of possible side effects. That entire experience was quite eye opening as far as insurance, the importance of being PROACTIVE as YOUR OWN patient advocate in a situation like that, and follow up/rehabilitation were all concerned. It can be very overwhelming, trying to live your life while being thrust into those circumstances. I had a double whammy that year as my best friend was in Cancer treatment at Memorial Sloan Kettering in NYC at the same time. Between both hospitals I was in at least one of them practically every day for months on end.

https://www.mayoclinic.org/diseases-con ... c-20362793

With all of that said, when I posted "Someone Get Me A Doctor...... Champions Of Imetelstat" back in April of this year, I had been troving through abstracts on Geron's website with Physicians/Clinicians who were connected on multiple studies on Imetelstat.

Dr. Amer M. Zeidan was not on my radar as being on multiple abstracts with the Imetelstat studies.

I did manage to find this abstract on ET/PV from 2020.......

https://www.ncbi.nlm.nih.gov/pmc/articl ... n_sectitle

"Telomeres are repetitive DNA sequences that shorten with each cell division thereby limiting the replicative potential of cells [79]. Telomere shortening has been shown to correlate with JAK2 V617F allele burden in PV and MF patients and could potentially contribute to genomic instability [1,80]. Conversely, telomerase activity is essential to maintain telomere length in rapidly dividing cells and has been documented in various cancers [81]. Following in-vitro studies showing that the telomerase inhibitor imetelstat was able to inhibit megakaryocyte proliferation in cells from ET patients, a subsequent phase II study (NCT01243073) showed hematologic responses in 100% (CHR 89%) and molecular responses in a majority of patients [82]. Additional in-vitro studies showed that imetelstat is specifically targeting neoplastic megakaryocytes while sparing normal megarkaryocytes [83,84]. Despite those promising results, no clinical trials using imetelstat in ET or PV patients are currently active."

"In summary, HU will likely remain the most frequently used therapy for most high-risk ET and PV patients but several alternatives such as ropegylated IFN, ruxolitinib, or novel agents (e.g. HDAC inhibitors, imetelstat) are promising. We are also about to enter a new era of genetically-driven and individualized prognostication and treatment approaches, but additional validation is needed at this time prior to routine use."

"Promising novel agents in clinical testing include the histone deacetylase inhibitor givinostat, the telomerase inhibitor imetelstat, and the LSD-1 inhibitor IMG-7289."


Also, the YCC or Smillow Cancer Center's website concerning Clinical Trials wasn't exactly user friendly, and the hour or so I spent researching, I couldn't find the P3 IMerge CT listed there, but it is listed as a location on Clinical Trial.gov......

https://clinicaltrials.gov/ct2/show/NCT ... 0#contacts

Bottom-line, Dr. Amer M. Zeidan* wasn't on my radar before, but perhaps now he should be.

Thank you for pointing this out!!

https://www.lls.org/award-recipient/amer-zeidan

https://www.yalemedicine.org/specialists/amer_zeidan



*Interesting side note, besides being a specialist in Myeloid Malignancies, Dr. Zeidan's research includes Leukemia and Lymphoma. -Kmall

biopearl123
Posts: 1665
Joined: Fri Jul 20, 2018 5:13 pm

Re: Dr María Díez‐Campelo (Spain): P3 IMerge (MDS).....

Post by biopearl123 » Fri Oct 28, 2022 7:58 pm

Kmall, yes, yet another world class institution directly involved in Imetelstat research.
Glad your father in law is doing ok. bp

Post Reply